Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells

Anticancer Research

Volumn 22, Issue 2 A, 2002, Pages 1007-1009

  De Soto, Joseph A ^a   Bowen, Donnell ^a   Davis, Jillian H ^a   Southerland, William M ^a   Hawkins Jr , Morris ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antagonism; Breast cancer cells; Methotrexate; Raloxifene

Indexed keywords

FOLIC ACID ANTAGONIST; METHOTREXATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MEGADOSE; GROWTH RATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; FEMALE; HUMANS; METHOTREXATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TUMOR CELLS, CULTURED;

EID: 0036244578     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Raloxifene reduces risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial
2. Antiestrogen action of raloxifene and tamoxifen: Today and tomorrow
3. Raloxifene reduces incident primary breast cancer: Integrated data from multi center, double-blind, placebo-controlled, randomized trials in postmenopausal women
4. Sequence-dependent antagonism between tamoxifen and methotrexate in human breast cancer cells
5. American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene
6. 1 cyclins and control of the cell division cycle in normal and transformed cells
7. Introduction to the E2F family: Protein structure and gene regulation